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Abstract
Rubinstein-Taybi syndrome (RTS) is a
well delineated multiple congenital
anomaly syndrome characterised by men-
tal retardation, broad thumbs and toes,
short stature, and specific facial features.
The recent localisation of the disorder to
16pl3.3 and subsequent identification of a
submicroscopic deletion of this region in
RTS patients led us to screen a large
cohort of affected subjects using the RT1
probe. Among 64 patients with clinical
evidence of RTS, seven (11%) had a
deletion. Another patient had a transloca-
tion of the region without evidence of a
deletion. The features of coloboma,
growth retardation, naevus flammeus,
and hypotonia have a positive predictive
value for the presence of an RT1 deletion.
Because of the relatively low frequency of
deletions in RTS, the RT1 probe is useful
in diagnostic confirmation, but has lim-
ited use as a screening tool.
(JMed Genet 1997;34:203-206)
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Originally described in 1963, Rubinstein-Taybi
syndrome (RTS) is a clinical diagnosis ofmen-
tal retardation, short stature, broad thumbs
and toes, and characteristic facial features.1
Although the specific aetiology is unknown,
there is evidence for a genetic basis. Several
reports of parent to child transmission with a
mild phenotype in the parent suggest a
dominant trait, although the diagnosis in these
cases has been questioned.2'3A breakthrough
in the search for a specific aetiology in RTS
occurred with the identification of cytogenetic
rearrangements involving 16pI3.3 in a few
patients with classical features of RTS.4-6 This
led to the creation of the cosmid RT1
(D16S237) which hybridises to a region within
16p13.3 encompassing the 3' end of the CBP
(cyclic AMP responsive binding (CREB)
protein) gene. This protein is ubiquitously
expressed as a coactivator in cyclic AMP regu-
lated gene expression.7 Using the RT1 probe,
Breuning et al" identified a deletion of this
region in six out of 24 RTS patients screened.
Masuno et al found an RT1 deletion in one out
of 25 RTS patients in Japan. McGaughan et al'0
identified two deletion patients in a group of 16
British RTS patients. To date, 65 RTS patients
have been screened with the cosmid RT1
(D16S237) probe with nine deletions identi-
fied.
We describe the results using the RT1 probe
to screen a North American cohort of 64 RTS
patients in order to establish the deletion
frequency in this population, to identify clinical
differences between deleted and non-deleted
patients, and to test the hypothesis that patients
with deletions may be more severely affected
than those without deletions.
Methods
ASCERTAINMENT
Sixty-four patients with the diagnosis of RTS
were ascertained through the Rubinstein-Taybi
Parent Group (47 (73%)) and referrals from
other genetic centres (17 (27%)). Clinical data,
photographs, and medical records were col-
lected on each patient to confirm the diagnosis
of RTS. Thirty-nine specific traits, including
growth parameters, were assessed for each
patient. Since RTS is a short stature syndrome,
microcephaly in this context was used as 1 SD
below the 50th centile height age to assess true
microcephaly in relation to body size and not
small head size resulting from overall growth
deficiency. Clinical assessment was made
before knowledge of deletion status to mini-
mise potential bias and to test the hypothesis
that there are clinically distinguishable differ-
ences between deletion and non-deletion
patients.
CYTOGENETIC STUDIES
Peripheral lymphocytes were cultured for 72
hours using conventional methods. Karyotyp-
ing with GTG banding was performed at the
550 to 750 band level. A minimum offive meta-
phase preparations were examined from each
patient.
MOLECULAR STUDIES
The RT1 cosmid (D16S237), approximately
56 kb in size, was obtained in an E coli MC
1046 host. The presence of the probe was con-
firmed by digestion with EcoRI, which yielded
a specific 5.2 kb fragment. The cosmid was
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Table 1 Clinicalfeatures ofRubinstein-Taybi patients
Current study Stevens et al'5
Deletion patients Non-deletion patients RTS patients
(%/) (%) (%)
Craniofacial
Curved nose
Grimacing smile
Epicanthic folds
Downward slanting palpebral
fissures
Micrognathia
Heavy arched eyebrows
Ptosis
Long eyelashes
Puffy face in infancy
Ear anomalies
Prominent forehead
Ophthalmological
Strabismus
Refractive error
Coloboma
Cataracts
Hypertelorism
Cardiac
Congenital heart defects
Orthopaedic
Stiff unsteady gait
Broad thumbs
Broad big toe
Other broad fingers
Polydactyly
Syndactyly
Clinodactyly
Radial deviation of thumb
Sternal abnormalities
Neurological
Hypotonia
Feeding difficulties
Seizures
Structural CNS abnormalities
Microcephaly
Growth retardation
Developmental delay
Dermatological
Hypertrichosis
Naevus flammeus
Urological
Cryptorchidism
Renal abnormalities
Endocrinological
Delayed bone age
Birth weight (average)
3/7 (43)
5/7 (71)
4/7 (57)
4/7 (57)
5/7 (71)
5/7 (71)
3/7 (43)
3/7 (43)
3/7 (43)
3/7 (43)
2/7 (28)
2/7 (28)
1/7 (14)
3/7 (43)
0/7 (0)
1/7 (14)
2/7 (28)
4/5 (80)
7/7 (100)
6/7 (85)
2/7 (28)
1/7 (14)
0/7 (0)
1/7 (14)
3/7 (43)
1/7 (14)
5/7 (71)
3/7 (28)
1/7 (14)
0/7 (0)
5/7 (71)
7/7 (100)
7/7 (100)
4/7 (57)
4/7 (57)
5/6 (83)
1/7 (14)
1/7 (14)
2485 g
43/57 (75)
29/57 (51)
28/57 (50)
39/57 (68)
31/57 (54)
24/57 (42)
15/57 (26)
27/57 (47)
20/57 (35)
37/57 (33)
19/57 (33)
22/57 (38)
23/57 (40)
3/57 (5)
2/57 (4)
14/57 (24)
23/57 (40)
27/54 (50)
57/57 (100)
49/57 (86)
19/57 (33)
5/57 (9)
4/57 (7)
13/57 (23)
23/57 (38)
11/57 (19)
27/57 (43)
20/57 (35)
5/57 (8)
2/57 (4)
30/57 (53)
35/51 (68)
57/57 (100)
21/57 (37)
15/57 (26)
21/33 (64)
2/57 (4)
11/57 (19)
3019 g
Other features noted in deletion patients include apnoea, autism, and neuroblastoma and IgG
subclass deficiency.
Other features in non-deletion patients include apnoea, depression, bipolar disorder, schizoid per-
sonality, supernumerary teeth, ulcerative colitis, IgG subclass deficiency, and supernumerary ribs.
labelled using the BioNick Labelling System
from Life Technologies Inc under conditions
optimised for biotin. The labelling reaction was
verified by the presence of a 300-400 base pair
band on agarose gel. A 7-8 ztg aliquot of
labelled RT1 cosmid was mixed with 500 gg
Human Cot DNA and 500 gg salmon sperm
DNA from Gibco BRL Inc as non-specific
blocking agents for a final volume of 150 gl.
Fluorescent in situ hybridisation was per-
formed on metaphase preparations under
standard conditions using a mixture of biotin
labelled RT1 probe and digoxigenin labelled a
satellite probe for chromosome 16 from Oncor
Inc. Two microlitres of the RT1 probe and 0.75
,ul of the 16 a satellite probe were added to 30
pt Hybrisol VI and denatured at 70°C for five
minutes before an overnight hybridisation.
Detection and DAPI (6-diamidino-2-
phenylindole) staining for dual colour were
carried out according to standard protocol. Ten
to 15 metaphases were evaluated on each
patient.
STATISTICAL METHODS
The presence or absence of 39 clinically
discernible traits was scored on each patient.
Multiple logistic regression with a stepwise
computed model using the True Epistat
(trademark) computer program was used to
analyse the data with presence or absence of a
deletion as the outcome criteria. The data were
analysed as a whole for overall differences, and
a predictive model was constructed using traits
with statistical significance of p>O. 10 (chi-
20/49 (40) square).
Results
CLINICAL FINDINGS
There were 64 patients in total with 33 males
24/50 (48) and 31 females (clinical findings are summa-
3/49 (6) rised in table 1). The age range of patients was
2 weeks to 56 years. All patients had broad
thumbs and distinctive facial features. Mental
19/50 (380 retardation was present in all those over 2 years
of age where mental retardation could be accu-
50/50 (100) rately assessed. Short stature (height <3rd cen-
50/50 (100) tile) was present in 48/64 (75%) of patients.
5/50 (10) Disproportionate microcephaly (head circum-ference more than 1 SD below height age) was
present in 17/41 (41 %) of patients. Congenital
19/50 (38) heart disease was present in 24/64 (39%) of
patients, which parallels the previously re-
ported incidence of congenital heart disease
(38%) in RTS.'1
CYTOGENETIC FINDINGS
Karyotype analysis showed a normal cytoge-
netic pattern at the 550 to 750 band level with
structurally normal chromosome 16 homo-
logues in 63/64 patients. A balanced transloca-
21/21 (100) tion (1;16) was identified in one patient. The
translocation is designated 46,XY,t(1;16)
(p34. l;p 13.2).
3090 g
FLUORESCENT IN SITU HYBRIDISATION
Using the RT1 cosmid, there were seven dele-
tions identified by the presence of only one
RT1 signal and two 16 a satellite signals in a
single patient, indicating a submicroscopic
deletion of the RT1 region. The translocation
patient showed two RT1 signals, one on chro-
mosome 16 and the other on the derivative
chromosome 1, indicating that the RT1 region
was not deleted, but moved from its usual posi-
tion by the translocation.
COMPARISON OF DELETION AND NON-DELETION
PATIENTS
A summary of the clinical features of deletion
and non-deletion patients is presented in table
1. The seven deletion patients had an age
distribution of 2 weeks to 10 years with a mean
age of 4.6 years. The sex distribution was six
males and one female. The non-deletion
patients ranged from 2 months to 56 years with
a mean age of 11.7 years. Growth retardation
was present in 7/7 (100%) of deletion patients
and 35/51 (68%) of non-deletion patients.
Disproportionate microcephaly was seen in 1/6
(16%) deletion patients and 16/35 (45%) non-
deletion patients. Congenital heart defects
were present in 2/7 (28%) deletion patients and
25/57 (40%) non-deletion patients. Broad toes
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Table 2 Prediction ofan RTI deletion using selected
Rubinstein-Taybi syndrome traits
Trait Odds ratio p value
Positive predictors
Growth retardation >100:1 0.10
Naevus flammeus 14:1 0.05
Coloboma 4.5:1 0.10
Hypotonia 3:1 0.10
Negative predictors
Prominent forehead 0.15:1 0.20
Refractive error 0.12:1 0.10
Using these six traits as predictors of deletion status,
sensitivity=87.5%, specificity=80%, false positive=61%, false
negative=2.2%, correct classification=81%.
Table 3 Frequency of deletions of 16p13.3 in
Rubinstein-Taybi syndrome
Total No of No of
patients deletions %
Breuning et alr 24 6 25
(The Netherlands)
Masuno et al' 25 1 4
(Japan)
McGaughan et al'° 16 2 12.5
(United Kingdom)
Present study 64 7 11
(USA)
Total 125 16 12.8
were present in 6/7 (85%) deletion patients and
25/57 (40%) non-deletion patients. Average
birth weight was 2845 g for deletion patients
and 3019 g for non-deletion patients. The
average number of the scored features was 18.4
in deleted patients and 16.7 in non-deleted
patients.
STATISTICAL ANALYSIS
Growth retardation (height, weight, and head
circumference <3rd centile), hypotonia, ocular
coloboma, naevus flammeus, prominent fore-
head, and refractive error were the subset of
traits with statistical significance. An RT1
deletion was more likely to be identified in
patients with growth retardation (odds ratio
>100:1), hypotonia (odds ratio 3:1), ocular
coloboma (odds ratio 4.5:1), and naevus flam-
meus (odds ratio 14:1). The presence of
prominent forehead and refractive error pre-
dicted non-deletion status with odds ratios of
0.15:1 and 0.12:1, respectively. Table 2 sum-
marises the odds ratios and statistical signifi-
cance of these traits as predictors of deletion
status. Using these six traits to create a predic-
tive model yielded a sensitivity of 87.5%,
specificity of 80%, false positive rate of 61%,
false negative rate of 2.2%, and correct
classification of 81%. This model accounted
for 38% of log likelihood probability of the
presence of an RT1 deletion. The model
chi-square was 18.3 with 6 degrees offreedom,
p=0.005.
Discussion
Rubinstein-Taybi syndrome is a multisystem
dysmorphic syndrome with many non-specific
features, making diagnosis occasionally diffi-
cult. Mental retardation, broad thumbs, short
stature, and characteristic facial features are
minimal diagnostic criteria. Epicanthic folds,
growth retardation, and arched eyebrows are
part of RTS, yet are not pathognomonic. The
availability of a molecular test would greatly aid
the clinician in the confirmation of this diagno-
sis. The creation of the RT1 probe seemed to
address this need.
Use of the RT1 probe has been reported in
three small series of RTS patients before this
series (table 3), primarily because of the rarity
of patients with RTS. Our study, the first series
in North America and the largest to date, dou-
bles the number ofRTS patients screened with
the RT1 probe. The frequency ofRT1 deletion
in our group is 7/64 (1 1%), which is compara-
ble to the pooled data from all studies, a dele-
tion frequency of 12.8%. As a result of these
data, the clinical use of the RT1 probe is
limited, as more than 87% of clinically affected
RTS patients would not be detected with this
probe. A deletion, however, would still confirm
the diagnosis.
The specific pathogenesis of the RTS
phenotype is still not clear. The RT1 region
contains the CBP (CREB binding protein)
gene, a cyclic AMP binding protein. Protein
truncation studies have identified abnormali-
ties of this protein in a small number of subjects
with RTS, suggesting that this gene is involved
in the RTS phenotype.'2 The role of CBP in
embryogenesis is currently unknown. The
multiple malformations of RTS would suggest
that its potential importance in morphogenesis
bears further study.'3 However, since deletions
have been found in only 12% of the RTS
patients studied, different mechanisms produc-
ing the syndrome must be present. A point
mutation within the CBP gene without dele-
tion would not be detected by the RT1 probe
and may be the mechanism in some patients.
Uniparental disomy of chromosome 16 has
been studied, but there is no evidence to
support this as an aetiological mechanism. "4
Alternatively, genetic heterogeneity involving
other loci is a possibility.
In general, our deleted patients do not seem
clinically distinct from their non-deleted coun-
terparts. Statistically, as a whole, they do not
present a different phenotype. Our initial
hypothesis that deleted patients might be more
severely affected was not borne out in our
population. This would support the notion of a
specific critical locus and not a contiguous gene
deletion syndrome.
Four features, all previously described in
RTS (growth retardation, coloboma, naevus
flammeus, and hypotonia), had a positive
predictive value for the presence of a deletion.
Two features of RTS patients (prominent fore-
head and refractive error) had a negative
predictive value for presence of a deletion.
While not conclusive, the presence or absence
of these features may be helpful to clinicians.
The benefit of establishing the presence of a
coloboma may suggest obtaining ophthalmo-
logical consultation as a routine part of the
RTS patient evaluation.
The RT1 probe may be useful for diagnostic
confirmation of a diagnosis ofRTS, but the low
detection frequency makes its benefit as a
screening test limited. Further molecular
analysis of people who do not have an RT1
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deletion is needed for clarification of the
genetic aetiology of this syndrome.
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